Molecular and Immunohistochemical Profiling of Tumors in Patients with Parathyroid Tumors

Launched by M.D. ANDERSON CANCER CENTER · Jan 30, 2017

Keywords

ClinConnect Summary

This clinical trial is focused on studying parathyroid tumors, which can be benign or cancerous growths in the parathyroid glands. Researchers aim to analyze the molecular and immunohistochemical features of these tumors. By doing this, they hope to improve the accuracy of diagnoses, reduce the chances of unnecessary surgeries, minimize complications, and provide better follow-up care for patients. Essentially, this study could help doctors understand these tumors better, leading to more effective treatment options for conditions like parathyroid adenoma, atypical adenoma, and parathyroid carcinoma.

To participate in this trial, you need to have a diagnosis of primary hyperparathyroidism and must have previously consented to allow your tissue or blood samples to be used for research. The study is open to all patients, regardless of age, gender, or ethnicity, as long as there is tissue available for analysis. If you qualify and choose to join, you can expect to contribute to important research that may enhance the future care of patients with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The patient cohort for this study consists of all patients within the prospectively maintained parathyroid database within the Department of Surgical Oncology at the University of Texas MD Anderson Cancer Center (MDACC) or from collaborating sites, with tissue or blood available from 1968-2015, previously consented for the use of the tissue for research purposes (via Protocols LAB 08-0034, PA11-0695 and LAB03-0320 or the appropriate external mechanism for collaborating sites).
• • All patients with a known diagnoses of primary hyperparathyroidism (PHPT) operated/treated in the Department of Surgical Oncology of MDACC or at a collaborating site. Patients that have provided consent for the use of the tissue or blood for research purposes will then be considered for our study (via Protocol LAB03-0320 and LAB 08-0034 or the appropriate external mechanism for collaborating sites).
• • All consented patients with known diagnoses of PHPT with a histopathological diagnosis of: parathyroid carcinoma, atypical parathyroid neoplasm or parathyroid adenoma. There will be no restrictions on age, gender, or ethnicity.
• • Selected patients obtained through outside collaboration who meet the selection criteria for tissue availability and diagnostic suitability for inclusion in the study.
• Exclusion Criteria:
• • Patients without tissue available for analysis.